Buradasınız

Doksorubisin ile Oluşturulmuş Deneysel Kardiyotoksisite Üzerine Nikotinamidin Etkisi

Effect of nicotinamide on doxorubicin induced experimental cardiotoxicity

Journal Name:

Publication Year:

Abstract (2. Language): 
Objectives: We investigated the morphologic changes showing cardiotoxicity caused by use of the doxorubicin which is an antineoplastic agent, and the protective effect of nicotinamide. Methods: We assigned thirty Wistar Albino male rats were randomly to four groups: Group 1 (Control) had %0.9 NaCl for 7 days, group 2 had Nicotinamide 200 mg/kg/day for 7 days, group 3 had single dose injection of Doxorubicin (20 mg/kg), group 4 had combination of Doxorubicin and Nicotinamide intraperitoneally. At the end of the experiment, the hearts were removed for light and electron microscopic investigations. We determined the tissue activites of catalase, glutathione-S-transferase, glutathione, glutathione peroxidase. Results: Control and Nicotinamide rats showed a normal heart tissue morphology. The rats in group 3 exhibited disorganization of the myocardial fibres, and infiltration of inflammatory cells. The rats in group 4 displayed a significant decrease in morphological damage, with the disappearance of inflammatory cell infiltration. Conclusion: Our findings suggested that the use of antioxidants of Nicotinamide may help to reduce Doxorubicin cardiotoxicity, thus contributing to clinical applications.
7-14

REFERENCES

References: 

1. Saad SY, Najjar TA, Al-Rikabi AC. The preventive role
deferoxamine against acute doxorubicin-induced cardiac,
renal and hepatic toxicity in rats. Pharmacol Res
2001; 43: 211-218.
2. Akkufl ‹. Serbest Radikaller ve fizyopatolojik etkileri.
Konya: Mimoza Yay›nlar›; 1995.
3. Kavas (Özelçi) G. Serbest radikaller ve organizma
üzerine etkileri. Türkiye Klinikleri 1989; 9: 1-8.
4. Meram ‹., Aktaran fi. Serbest radikallerin biyomoleküller
üzerine etkileri. Arfliv 2002; 1: 299-304.
5. Ya¤murca A, Bas O, Mollaoglu H, et al. Protective
effects of erdosteine on doxorubicin-induced hepatotoxicity
in rats. Arch Med Res 2007; 38: 380-385.
6. Wojtacki J, Lewicka-Nowak E, Lesniewski-Kmak K.
Anthracycline-induced cardiotoxicity: clinical course,
risk factors, pathogenesis, detection and prevention
review of the literature. Med Sci Monit 2000; 6: 411-
412.
7. Tanr›verdi G. Karbon tetraklorür (CCL4) ile oluflturulmufl
karaci¤er hasar›nda de¤iflik dozlardaki nikotinamidin
protektif etkisinin ›fl›k ve elektron mikroskobik
olarak incelenmesi [Yüksek Lisans Tezi]. ‹stanbul:
‹.Ü.Cerrahpafla T›p Fakültesi Histoloji ve Embriyoloji
A.D.; 2005.
8. Cuzzocrea S, Riley DP, Caputi AP, Salvemini D, et al.
Antioxidant therapy: a new pharmacological approach
in shock, inflammation, and ischemia/reperfusion
injury. Pharmacol Rev 2001; 53: 135-159.
9. Damc› T. Koruyucu giriflimler. Diabetes Mellitus Sempozyumu.
‹stanbul; 151-156.
10. Beutler E, Blurne KG, Kaplan JC, et al. International
Comitte for Standardization in Haematology: Recommended
methods for red blood cell enzyme analysis.
Br J Haematol 1977; 35: 331-340.
11. Habig WH, Pabst MJ, Jacob WB. Glutathione-S-transferase.
The first enzymatic step in mercapturic acid
formation. J Biol Chem 1974; 249: 7130-7139.
12. Aebi H. Catalase. In: Bergmeyer H.U, ed. Metods of
enzymatic analysis. Newyork: Academic Press; 1974;
673-677.
13. Levine RL, Garland D, Oliver CV, et al. Determination
of carbonyl content in oxidatively modified proteins.
Meth Enzymol 1990; 186: 464-473.
14. Kayaalp O. Rasyonel tedavi yönünden t›bbi farmakoloji.
Ankara: Günefl Bas›mevi; 2000; 1011-1013.
15. Singal PK, Iliskovic N, Kumar D. Adriamycin cardiomyopathy:
pathophysiology and prevention. FASEB J
1997; 11: 931-936.
16. el-Shazly MO, Afify MM, el-Dieb MK. Histopathological
study into side-effect toxicity of some drugs used
in treatment of cancer. Arch Exp Veterinarmed 1989;
43: 319-326.
17. Fadillioglu E, Oztas E, Erdo¤an H, et al. protective effects
of caffeic acid phenethyl ester on doxorubicininduced
cardiotoxicity in rats. J Appl Toxicol 2004;
24: 47-52
18. Sacco G, Bigio M, Evangelista S, et al. Cardioprotective
effects of zofenopril, a new angiotensin-converting
enzyme inhibitor, on doxorubicin-induced cardiotoxicity
in the rat. Eur J Pharmacol 2001; 414: 71-78.
Cerrahpafla T›p Derg 2008; 39(1): 7-14
19. Venditti P, Balestrieri M, De Leo T, Di Meo S. Free
radical involvement in doxorubucin-induced electrophysiological
alterations in rat papillary muscle fibres.
Cardiovasc Res 1998; 38: 695-702.
20. Siveski-‹liskovic N, Kaul N, Signal PK. Probucol prometes
endogenous antioxidants and provides protection
against adriamycin-induced cardiomyopathy in
rats. Circulation 1994; 89: 2829-2835.
21. Sadzuka Y, Sugiyama T, Shimoi K, et al. Protective effect
of flavonoids on doxorubicin-induced cardiotoxicity.
Toxicol Lett 1997; 92: 1-7.
22. Myers C. The role of iron in doxorubicin-induced cardiomyopathy.
Semin Oncol 1998; 25: 10-14.
23. Malarkodi PK, Balachandar AV, Varalakshmi P. Protective
effect of lipoic acid on adriamycin induced lipid
peroxidation in rat kidney. Mol Cell Biochem
2003; 247: 9-13.
24. Tesoriene L, Ciaccio M, Valenza M, et al. Effect of vitamin
A administration on resistance of rat heart against
doxorubicin-induced cardiotoxicity and lethality.
J Pharm Exp Ther 1994; 269: 430-6.
25. Van Vlett JF, Ferrans VJ, Weirich WE. Cardiac disease
induced by chronic adriamycin administration in
dogs and an evaluation of vitamin E and selenium as
cardioprotectants. Am J Pathol 1980; 99: 13-42.
26. Balli E, Mete ÖU, Tuli A, et al. Effect of melatonin on
the cardiotoxicity of doxorubicin. Histol Histopatol
2004; 19: 1101-1108.
27. Ungersted JS, Blömback M, Söderström T. Nicotinamide
is a potent inhibitor of proinflammatory cytokines.
Clin Exp Immunol 2003; 131: 48-52.
28. Fukuzawa M, Satoh J, Muto G, et al. ‹nhibitory effect
of nicotinamide on in vitro and in vivo production of
tumor necrosis factor-alpha. Immunol Lett 1997; 59:
7-11.

Thank you for copying data from http://www.arastirmax.com